CAR-T therapy, as a promising new cancer immunotherapy method, has achieved significant success in the treatment of non-solid tumors and made breakthroughs in the treatment of solid tumors and other challenging diseases. However, the personalized preparation process of CAR-T and the high cost greatly limit its application. CAR-T mRNA drugs utilize the transient expression characteristic of mRNA to temporarily modify T cells in the body safely, transforming CAR-T technology from personalized therapy into a universal tumor drug. At the same time, it also reduces the risk of exogenous biological contamination, providing a new approach for cancer treatment.

EnoBio provides an integrated solution covering the entire value chain from CAR structure construction to clinical sample production and regulatory submission. Clients can choose integrated or single-module/technical point solutions based on their needs, including AI-guided CAR structure protein design (DMC.AI platform), CAR structure mRNA design and synthesis, safe and efficient transfection of T cells using targeted LNP delivery systems, immunostimulatory cap analogs, immunostimulatory UTR and poly A tails, etc. With the combination of proprietary technology, key raw materials, and R&D production equipment supply chain, EnoBio can not only solve the comprehensive cost issues of CAR-T mRNA drug products but also meet the development of various CAR structures and related drug needs with full control over the entire chain.

Comparison between traditional CAR-T and CAR-T processes:

case study:

Heart failure, as the final stage of heart disease progression, currently lacks effective treatment options. Heart failure is typically driven by fibroblasts, which respond to cardiac injury and inflammation (fibrotic processes) by producing excessive fibrous material, leading to myocardial stiffening and impaired cardiac function. Using T cells targeted to lipid nanoparticles (LNPs) as carriers to deliver mRNA encoding T cell receptors targeted to activated fibroblasts, a large number of transient CAR-T cells are generated in vivo to attack the fibroblasts responsible for heart failure. This approach significantly reduces cardiac fibrosis in a heart failure mouse model, restoring most of the heart's normal size and function, with no evidence of sustained anti-fibroblast T cell activity one week after treatment. This represents a transient and controllable in vivo cell therapy, offering advantages of lower cost and increased safety and control compared to traditional CAR-T therapy, which risks prolonged inhibition of fibroblast numbers and impaired wound healing due to the extended presence of CAR-T cells in the body1.

1. CAR T cell produced in vivo to treat cardiac injury. . 2022. 375(6576):91

Development process:

* Available proprietary intellectual property solutions